Drs L.E. Hillege, M.D.

Russ, E., Ziemons, J., Hillege, L. E., van Kuijk, S. M. J., de Jong, E. M., Elbers, C., Deenen, M. J., Borghuis, L. H., Bohm, T. M. M., Kristen, P., Valk, L. C., van Hellemond, I. E. G., Vestjens, H., Dietvorst, A., Baars, A., Goosens, A. N. M., Vermeulen, L., Buffart, T. E., de Vos-Geelen, J., ... Smidt, M. L. (2025). Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer-study protocol of the OPTIMA study. BMC Cancer, 25(1), Article 1129. https://doi.org/10.1186/s12885-025-14500-6

Hillege, L. E., Trepka, K. R., Guthrie, B. G. H., Fu, X., Aarnoutse, R., Paymar, M. R., Olson, C., Zhang, C., Ortega, E., Ramirez, L., de Vos-Geelen, J., Valkenburg-van Iersel, L., van Hellemond, I. E. G., Baars, A., Vestjens, J. H. M. J., Penders, J., Deutschbauer, A., Atreya, C. E., Kidder, W. A., ... Turnbaugh, P. J. (2025). Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. Mbio, 16(6). https://doi.org/10.1128/mbio.00930-25

Hillege, L. E., Barnett, D. J. M., Ziemons, J., Aarnoutse, R., de Vos-Geelen, J., van Geel, R., de Boer, M., van Riet, Y. E. A., Vincent, J., Penders, J., & Smidt, M. L. (2025). The gut microbiota during tamoxifen therapy in patients with breast cancer. Scientific Reports, 15(1), Article 7874. https://doi.org/10.1038/s41598-025-91734-1

Hillege, L. E., Stevens, M. A. M., Kristen, P. A. J., de Vos-Geelen, J., Penders, J., Redinbo, M. R., & Smidt, M. L. (2024). The role of gut microbial ß-glucuronidases in carcinogenesis and cancer treatment: a scoping review. Journal of Cancer Research and Clinical Oncology, 150(11), Article 495. https://doi.org/10.1007/s00432-024-06028-2

Ziemons, J., Hillege, L. E., Aarnoutse, R., de Vos-Geelen, J., Valkenburg-van Iersel, L., Mastenbroek, J., van Geel, R., Barnett, D. J. M., Rensen, S. S., van Helvoort, A., Dopheide, L. H. J., Roeselers, G., Penders, J., Smidt, M. L., & Venema, K. (2024). Prebiotic fibre mixtures counteract the manifestation of gut microbial dysbiosis induced by the chemotherapeutic 5-Fluorouracil (5-FU) in a validated in vitro model of the colon. BMC Microbiology, 24(1), Article 222. https://doi.org/10.1186/s12866-024-03384-4

Dieleman, S., Hillege, L., Ziemons, J., Kooreman, L., Penders, J., Boleij, A., Grabsch, H., & Smidt, M. (2023). Microbiota immuuninteracties bij kankerontwikkeling en behandeling. Nederlands Tijdschrift voor Leefstijlgeneeskunde, 1(4), 177-182.

Ziemons, J., Aarnoutse, R., Heuft, A., Hillege, L., Waelen, J., de Vos-Geelen, J., Iersel, L. V. V., van Hellemond, I. E. G., Creemers, G. J. M., Baars, A., Vestjens, J. H. M. J., Penders, J., Venema, K., & Smidt, M. L. (2023). Fecal levels of SCFA and BCFA during capecitabine in patients with metastatic or unresectable colorectal cancer. Clinical and Experimental Medicine, 23(7), 3919-3933. https://doi.org/10.1007/s10238-023-01048-7

Hillege, L., Waelen, J., Ziemons, J., Aarnoutse, R., De Vos-Geelen, J., De Boer, M., Van Riet, Y., Vincent, J., Venema, K., Rensen, S., Simpson, J., Redinbo, M., Penders, J., & Smidt, M. (2022). Bacterial beta-glucuronidase activity in postmenopausal breast cancer patients: a pilot study. European Journal of Cancer, 175, S84-S84. https://doi.org/10.1016/S0959-8049(22)01578-7